RSCM
RCUS icon

Rock Springs Capital Management’s Arcus Biosciences RCUS Stock Holding History

Rock Springs Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.55M Hold
180,000
– – 0.27% 71
2026
Q1 		$3.89M Hold
180,000
– – 0.23% 70
2025
Q4 		$4.29M Buy
+180,000
New +$3.67M 0.22% 74

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Rock Springs Capital Management's RCUS Position: Q2 2026 in Review

Rock Springs Capital Management held its Arcus Biosciences (RCUS) position steady in Q2 2026 at 180,000 shares worth $5.55M. The position accounts for 0.27% of the portfolio, ranked #71.

Rock Springs Capital Management first reported a position in RCUS in Q4 2025 and has held it in 3 quarters since. 230 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Rock Springs Capital Management held 180,000 shares of Arcus Biosciences worth $5.55M as of Q2 2026.
  • Rock Springs Capital Management left its Arcus Biosciences share count unchanged in Q2 2026.
  • Arcus Biosciences made up 0.27% of Rock Springs Capital Management's portfolio in Q2 2026, its #71 holding.
  • Rock Springs Capital Management first reported a position in Arcus Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 230 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.